Equity · Currency in KRW · Last updated Jun 5, 2026
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; Hearticellgram_AMI, a cardiac disease drug; Cellgram_CKD for the treatment of chronic kidney disease; and Cellgram_AKI for the treatment of acute kidney disease. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, as well as clinical development and commercialization services for new drugs. Further, it operates Twelve, a stem cell bank; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Looking to balance out your exposure to 005690.KS? The ETFs below have the lowest correlation with 005690.KS — they tend to move on their own, which can help reduce risk when 005690.KS drops. The stock ideas table highlights individual companies that behave independently from 005690.KS.
No Diversifiers Found for 005690.KS
We do not have enough correlation history to rank diversifiers for this symbol yet.
Diversification Analysis
Build a portfolio that complements 005690.KS
Add 005690.KS to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.
